Myeloproliferative Neoplasms Flashcards

(35 cards)

1
Q

what are myeloproliferative neoplasms (MPNs)?

A

clonal haematopoietic stem cell disorders with an increased production of one or more types of haemopoietic cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what do MPNs result in?

A

increased production of mature, differentiated cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are the two groups of MPNs?

A

BCR-ABL1 negative diseases

BCR-ABL1 positive diseases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

name three BCR-ABL 1 MPNs?

A

polcythaemia vera
primary myelofibrosis
essential thrombocythaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

name a BCR-ABL 1 positive MPN

A

chronic myeloid leukaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what happens in CML?

A

the proliferation of myeloid cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

how does CML present?

A

can be asymptomatic
splenomegaly
gout
hypermetabolic symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what features are seen on the blood count in CML?

A

normal or reduced HB
leucocytosis with neutrophilia, eosinophilia and basophilia
thrombocytosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what bone marrow change is seen in CML?

A

increased cellularity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what is the genetic hallmark of CML?

A

the philadelphia chromosome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what does the philadelphia chromosome result in?

A

formation of a new gene - BCR-ABL1

results in production of a tyrosine kinase with causes abnormal phosphorylation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what drugs can be given for CML?

A

tyrosine kinase inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

name a tyrosine kinase inhibitor

A

imatinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are the features common to MPNs?

A
may be asymptomatic 
gout 
fatigue 
weight loss 
sweats 
splenomegaly 
thrombosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is erythromelalgia?

A

redness and pain in the hands and feet due to microvascular occlusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what blood count changes are seen in polycythemia vera (PV)?

A

high Hb/haematocrit accompanied by erythrocytosis

17
Q

what can cause secondary polcythaemia?

A

chronic hypoxia

18
Q

what can causes pseudopolycythaemia?

A

dehydration
diuretic therapy
obesity

19
Q

how does PV present?

A

headache
fatigue
aquagenic pruritus

20
Q

what genetic mutation is seen in PV?

A

JAK2 mutations - seen in 95% of patients

21
Q

what is the main aim of treatment for PV?

A

reduce thrombosis risk

22
Q

how is PV managed?

A

venesect to haematocrit <0.45
aspirin
cytotoxic oral chemotherapy

23
Q

what chemotherapy drug can be given for PV?

A

hydroxycarbamide

24
Q

what happens in essential thrombocythaemia (ET)?

A

overproduction of platelets

25
what is there a risk of in ET?
thrombosis
26
what genetic mutations can be seen in ET?
JAK2 CALR MPL some patients are "triple negative" and have no mutations
27
what is the characteristic bone marrow appearance in ET?
increased amounts of abnormal looking megakaryocytes
28
how is ET managed?
aspirin | cytoreductive therapy to control proliferation
29
what drugs can be involved in the cytoreductive therapy in ET?
hydroxycarbamide anagrelide interferon alpha
30
how does primary myelofibrosis (PMF) present?
marrow failure splenomegaly hypercatabolism
31
what is seen on the blood film in PMF?
tear drop shaped RBC | leucoerythroblastic changes
32
what does leucoerythroblastic mean?
the presence of neutrophil and red cell precursors
33
what mutations can be seen in PMF?
JAK2 CALR MPL
34
how is PMF managed?
supportive care JAK2 inhibitors allogenic stem cell transplant in very few patients
35
name a JAK2 inhibitor
ruxolitinib